Schedule of Stock-Based Compensation Awards Granted

The consolidated stock-based compensation expense recognized by each of PAVmed Inc. and Lucid Diagnostics Inc. for both the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc. 2018 Equity Plan, with respect to stock options and restricted stock awards as discussed above, for the periods indicated, was as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Cost of revenue	$	9	$	—	$	9	$	—
Sales and marketing expenses		643		327		1,859		814
General and administrative expenses		3,854		3,353		12,016		9,088
Research and development expenses		258		310		699		727
Total stock-based compensation expense	$	4,764	$	3,990	$	14,583	$	10,629

Schedule of Unrecognized Compensation Expense

The consolidated unrecognized stock-based compensation expense and weighted average remaining requisite service period with respect to stock options and restricted stock awards issued under each of the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc. 2018 Equity Plan, as discussed above, is as follows:

	Unrecognized Expense		Weighted Average Remaining Service Period (Years)
PAVmed Inc. 2014 Equity Plan
Stock Options	$	8,424		2.1
Restricted Stock Awards	$	1,222		0.9

Lucid Diagnostics Inc. 2018 Equity Plan
Stock Options	$	3,791		2.4
Restricted Stock Awards	$	7,165		0.8

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Schedule of Restricted Stock Award Activity

PAVmed Inc. restricted stock awards granted under the PAVmed Inc. 2014 Equity Plan and restricted stock awards granted outside such plan are summarized as follows:

	Number of Restricted Stock Awards			Weighted Average Grant Date Fair Value
Unvested restricted stock awards as of December 31, 2021		1,666,666		$	2.36
Granted		—			—
Vested		(541,666	)		1.20
Forfeited		(150,000	)		2.04
Unvested restricted stock awards as of September 30, 2022⁽¹⁾		975,000		$	3.05

⁽¹⁾	The unvested restricted stock awards presented in the table above, are inclusive of 100,000 restricted stock awards granted outside the PAVmed Inc. 2014 Equity Plan as of September 30, 2022 and December 31, 2021.

Schedule of Summarizes Information About Stock Options

Lucid Diagnostics Inc. stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan and stock options granted outside such plan are summarized as follows:

	Number of Stock Options			Weighted Average Exercise Price		Remaining Contractual Term (Years)		Intrinsic Value⁽²⁾
Outstanding stock options at December 31, 2021		1,419,242		$	0.73		7.0	$	6,665
Granted⁽¹⁾		2,320,000		$	3.71
Exercised		(964,717	)	$	0.72
Forfeited		(141,436	)	$	4.33
Outstanding stock options at September 30, 2022⁽³⁾		2,633,089		$	3.17		8.6	$	499
Vested and exercisable stock options at September 30, 2022		960,364		$	2.33		7.2	$	499

⁽¹⁾	Stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan and those granted outside such plan generally vest ratably over twelve quarters, with the vesting commencing with the grant date quarter-end, and have a ten-year contractual term from date-of-grant.
⁽²⁾	The intrinsic value is computed as the difference between the quoted price of the Lucid Diagnostics Inc. common stock on each of September 30, 2022 and December 31, 2021 and the exercise price of the underlying Lucid Diagnostics Inc. stock options, to the extent such quoted price is greater than the exercise price.
⁽³⁾	The outstanding stock options presented in the table above, are inclusive of 423,300 stock options granted outside the Lucid Diagnostics Inc. 2018 Equity Plan, as of September 30, 2022 and December 31, 2021.

Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions

	Nine Months Ended September 30,
	2022
Expected term of stock options (in years)		5.8
Expected stock price volatility		72.0	%
Risk free interest rate		3.2	%
Expected dividend yield		—	%